KADCYLA Trastuzumab 100mg & 160mg Injection

Kadcyla (Trastuzumab) is a prescription drug  used to treat HER2- positive breast cancer that has spread to other parts of the body.

Manufacturer : Roche Products India Pvt Ltd

Strengths available :  100mg & 160mg

Storage : Store at temperature between 2°C – 8°C

Dosage :

The recommended dose of KADCYLA is 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. Do not administer KADCYLA at doses greater than 3.6 mg/kg. Do not substitute KADCYLA for or with trastuzumab.

Closely monitor the infusion site for possible subcutaneous infiltration during drug administration.

First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever, chills, or other infusion-related reactions.

Subsequent infusions : Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion.

Side effects : Nausea, Headache, Rash, Reduced blood platelets, Congestive cardiac failure, Insomnia (difficulty in sleeping), Infection, Upper respiratory tract infection, Nasopharyngitis, Fatigue, Fever, Anemia, Chills, Diarrhoea, Cough, Weight loss, Altered taste, Mucosal inflammation, Decreased white blood cell count (neutrophils), Stomatitis (Inflammation of the mouth).

Pack of 1 Vial